newsfilter
← Latest News
Business Wire·

Gossamer Bio Announces Completion of Enrollment in Registrational Phase 3 PROSERA Study for the Treatment of PAH

- Enrollment Completed in Ongoing Registrational PROSERA Phase 3 Study in PAH - - Topline Results Announcement from PROSERA Phase 3 Expected in February 2026 - - Blinded Preliminary Baseline Characteristics Align